R.A. Session, II net worth and biography

R.A. Session, II Biography and Net Worth

RA Session II is the President, CEO and Founder of Taysha Gene Therapies. Mr. Session has nearly 20 years’ experience in the life sciences industry, primarily in business development, corporate strategy and financial roles. Previously, he served as Chief Business Officer of the gene therapy subsidiaries of BridgeBio, as well as Senior Vice President of Corporate Strategy and Business Development at AveXis.

How do I contact R.A. Session, II?: The corporate mailing address for Mr. Session, II and other Taysha Gene Therapies executives is 2280 Inwood Road, DALLAS TX, 75235. Taysha Gene Therapies can also be reached via phone at 214-612-0000 and via email at [email protected]. Learn More on R.A. Session, II's contact information.
Has R.A. Session, II been buying or selling shares of Taysha Gene Therapies?: R.A. Session, II has not been actively trading shares of Taysha Gene Therapies during the last quarter. Learn More on R.A. Session, II's trading history.
Who are Taysha Gene Therapies' active insiders?: Taysha Gene Therapies' insider roster includes Kamran Alam (CFO), Phillip Donenberg (Director), Paul Manning (Director), Sean Nolan (Director), and R.A. Session, II (CEO). Learn More on Taysha Gene Therapies' active insiders.
Are insiders buying or selling shares of Taysha Gene Therapies?: In the last twelve months, Taysha Gene Therapies insiders bought shares 1 times. They purchased a total of 1,333,333 shares worth more than $2,999,999.25. The most recent insider tranaction occured on June, 27th when Major Shareholder Paul B Manning bought 1,333,333 shares worth more than $2,999,999.25. Insiders at Taysha Gene Therapies own 2.7% of the company. Learn More about insider trades at Taysha Gene Therapies.
Information on this page was last updated on 6/27/2024.

R.A. Session, II Insider Trading History at Taysha Gene Therapies

R.A. Session, II Buying and Selling Activity at Taysha Gene Therapies

Taysha Gene Therapies Company Overview

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Today's Range

Now: $2.04

$2.00

$2.07

50 Day Range

MA: $2.15

$1.27

$3.24

2 Week Range

Now: $2.04

$1.19

$4.32

Volume

273,671 shs

Average Volume

2,845,311 shs

Market Capitalization

$418.08 million

P/E Ratio

3.22

Dividend Yield

N/A

Beta

0.79

This drone stock is setting up to transform medical supply delivery

From The Tomorrow Investor | Ad

Drone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.

Click here to see how a new partnership could catapult this drone suppliers' growth